End of day dyskinesia in advanced Parkinson's disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation

@article{Apetauerova2006EndOD,
  title={End of day dyskinesia in advanced Parkinson's disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation},
  author={D. Apetauerova and Ruby K. Ryan and Susie I Ro and Jeffrey E. Arle and Jay L. Shils and Efstathios Papavassiliou and Daniel Tarsy},
  journal={Movement Disorders},
  year={2006},
  volume={21}
}
We report the therapeutic effects of deep brain stimulation (DBS) in 2 patients with Parkinson's disease (PD) with severe end of dose dyskinesia that was resistant to medical therapy. In both patients, severe, end of day ballistic dyskinesias occurred when the last levodopa dose of the day was wearing off. Globus pallidus (GPi) DBS in 1 case and subthalamic (STN) DBS in the second case produced full resolution of end of day dyskinesia. © 2006 Movement Disorder Society 
Sustained Dyskinesias Following Elective Cessation and Reactivation of Chronic Subthalamic Nucleus Deep Brain Stimulation for a Surgical Procedure
TLDR
A patient with previously well‐controlled dyskinesias who had severe and prolonged dyskineias following reactivation of deep brain stimulation (DBS) following an orthopedic procedure is reported. Expand
Parkinson’s Disease: Diphasic Dyskinesia
Diphasic dyskinesia (DD) is a complex pattern of levodopa (LD) dyskinesia in patients with Parkinson’s disease (PD) in which involuntary movements occur during both peak and trough LD effects. End ofExpand
The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
TLDR
The results show that the subthalamic nucleus plays a role, if modest, in the physiopathology of dyskinesias, and that chronic L-DOPA treatment does not modify the abnormal STN activity induced by the 6-hydroxydopamine lesion of the nigrostriatal pathway. Expand
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
TLDR
Dyskinesia is suggested to be considered as a factor in a signal-to-noise ratio (SNR) equation where the signal is the voluntary movement and the noise is PD symptomatology, including dysKinesia. Expand
High-Frequency Stimulation for Parkinson’s Disease and Effects on Pathways in Basal Ganglia Network Model
Deep brain stimulation of nuclei in the basal ganglia has been recognized as the most effective neurosurgical therapy for hypokinesia in patients with Parkinson’s disease; however, the mechanismExpand
Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
TLDR
Although both amantadine and deep brain stimulation help reduce LID, these approaches have complications that limit their wide use, and a novel antidyskinetic drug is strongly needed; these require us to understand the circuit mechanism of LID more deeply. Expand
Botulinum toxin as a treatment for tardive dyskinesia
TLDR
Two older female patients with a history of psychotic depression treated with a combination of an antipsychotic and an antidepressant developed persistent tardive dyskinesia with severe tongue protrusion and chose to continue taking botulinum toxin. Expand
Reply to Comment on: Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated “Biphasic‐Like” Dyskinesia with Pallidal Deep Brain Stimulation
TLDR
In this vignette, the life-changing effects of successful GPi DBS for levodopa-carbidopa intestinal gel-associated biphasic-like dyskinesia is illustrated. Expand
NMDA receptor antagonism potentiates the l-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats
TLDR
The present study does not support the hypothesis that DA-ergic degeneration influences the STN GLU levels neither that MK 801 alters theGLU levels in lesioned and non-lesioned rats, however, NMDA receptor antagonists could be used as a beneficial adjuvant treatment for PD by enhancing the therapeutic efficacy of l-DOPA at least in part in theSTN. Expand
Characterizing Deep Brain Stimulation effects in computationally efficient neural network models
TLDR
Efficient models of these neural structures were built, which are able to show, without any external input, the intrinsic properties of a pathological neural tissue, mimicking the BG synchronized dynamics, to investigate the effects of electrical stimulation on pathologically synchronized clusters of neurons. Expand
...
1
2
...

References

SHOWING 1-10 OF 22 REFERENCES
Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment
TLDR
In two patients with Parkinson's disease, addition of a direct‐acting dopamine receptor agonist was helpful in ameliorating this complication of anitparkinson therapy. Expand
Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations
TLDR
Bilateral DBS of STN is a significant progress in treatment of advanced idiopathic Parkinson's disease with levodopa‐induced motor complications and, on medication, a significant reduction in duration of dyskinesias and duration of off‐periods. Expand
l-Dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction
TLDR
Data support dopaminergic stimulation and striatal desensitization as major determinants of LID in PD. Expand
Opposite motor effects of pallidal stimulation in Parkinson's disease
TLDR
There are at least two different functional zones within the globus pallidus within the GPi, at the basis of a different pathophysiology of the cardinal symptoms of PD, which may explain the variable results of pallidal surgery reported in the literature and largely explain the paradox of PD surgery. Expand
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
TLDR
Investigation in eight patients with fluctuating Parkinson's disease complicated by functionally disabling off-period dystonia found chronic high-frequency stimulation of the subthalamic nucleus allows a very gradual increase in stimulation parameters with increasing beneficial effect on parkinsonism while reducing the threshold for the elicitation of stimulation-induced dyskinaesias. Expand
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.
TLDR
Bilateral stimulation of the subthalamic nucleus or pars interna of the globus pallidus is associated with significant improvement in motor function in patients with Parkinson's disease whose condition cannot be further improved with medical therapy. Expand
Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification
TLDR
Clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism. Expand
Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report.
TLDR
It is demonstrated that high-frequency electrical stimulation dorsal to the subthalamic nucleus (STN) can directly suppress levodopa-induced dyskinesias independent of dopaminergic medication changes. Expand
[Tardive dystonia].
TLDR
Investigation of the pharmacotherapy of the dystonia concerns mostly treatment with dopamine depletors or with high doses of anticholinergic agents, although total recovery is rare. Expand
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.
TLDR
Ballistic and dystonic involuntary movements occurring at the beginning and end of the period of levodopa efficacy are described in nine patients exhibiting dyskinesis during long-term levodOPA therapy, which were reduced by increasing and fractionating the daily doses of Levodopa. Expand
...
1
2
3
...